Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 1/20 | 0.52 |
| ▸ | GRPR | P30550 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 4/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.50 |
| ▸ | GIPR | P48546 | 7/20 | 0.48 |
| ▸ | GLP1R | P43220 | 6/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPY4R | P50391 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018377 | 0.96 | CXCR4 (0.54) | CXCR4GIPRGLP1RNPY1RNPY2R | |
| SCHEMBL22018326 | 0.93 | NTSR2 (0.51) | NMBRGRPRCXCR4GIPRGLP1R | |
| SCHEMBL25531559 | 0.93 | CXCR4 (0.50) | CXCR4GIPRGLP1R | |
| SCHEMBL25524956 | 0.92 | NMUR2 (0.51) | — | |
| SCHEMBL25524938 | 0.90 | APLNR (0.44) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL25524928 | 0.90 | APLNR (0.45) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL25524955 | 0.89 | NMUR2 (0.52) | NMBRGRPRNPY1RNPY2RNPY4R | |
| SCHEMBL30933128 | 0.88 | CXCR4 (0.56) | CXCR4GIPRGLP1R | |
| SCHEMBL25524962 | 0.88 | NMUR2 (0.46) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22018374 | 0.88 | F2 (0.52) | NMBRGRPRGIPRGLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | NMBR 1197/4885GRPR 35/4885CCKBR 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.